<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320794">
  <stage>Registered</stage>
  <submitdate>8/11/2009</submitdate>
  <approvaldate>9/11/2009</approvaldate>
  <actrnumber>ACTRN12609000965202</actrnumber>
  <trial_identification>
    <studytitle>Remote Ischaemic Preconditioning in High Risk Adult Cardiac Surgery</studytitle>
    <scientifictitle>A Partially Blinded Randomised Trial in Adults Undergoing High Risk Cardiac Surgery Comparing the Effect of Remote Ischaemic Preconditioning with no Remote Ischaemic Preconditioning on Inotrope Requirements, Renal Failure and Myocardial infarction in the Perioperative Period</scientifictitle>
    <utrn>U1111-1112-4333</utrn>
    <trialacronym />
    <secondaryid>Ischaemic Preconditioning</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adult cardiac surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A blood pressure cuff will be inflated to 200mmHg on an upper limb for five minutes and then deflated for five minutes.  This cycle will be repeated three times.  The intervention will be performed after induction of anaesthesia prior to onset of cardiopulmonary bypass</interventions>
    <comparator>A blood pressure cuff will be placed on the arm but not inflated.  The intervention will be performed after induction of anaesthesia prior to the onset of cardiopulmonary bypass</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>cumulative total inotrope use after cardiac surgery (total administered dose in mcg/kg will be recorded prospectively on the study datasheet)</outcome>
      <timepoint>3,6,12 and 24 hours following removal of aortic cross clamp during weaning from cardiopulmonary bypass</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Post-operative worst level of acute kidney injury based on RIFLE criteria</outcome>
      <timepoint>Post-operative period up until hospital discharge</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>serum troponin</outcome>
      <timepoint>6 and 12 hours following removal of aortic cross clamp during weaning from cardiopulmonary bypass</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time until ready for extubation</outcome>
      <timepoint>post-operatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>proportion of patients extubated</outcome>
      <timepoint>12 hours following removal of aortic cross clamp during weaning from cardiopulmonary bypass</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Interleukin 6 levels in blood (blood analysis)</outcome>
      <timepoint>0, 1, 2, 3, 6, 12 hours following removal of aortic cross clamp during weaning from cardiopulmonary bypass</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Interleukin 8 levels in blood (blood analysis)</outcome>
      <timepoint>0, 1, 2, 3, 6, 12 hours following removal of aortic cross clamp during weaning from cardiopulmonary bypass</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Interleukin 10 levels in blood (blood analysis)</outcome>
      <timepoint>0, 1, 2, 3, 6, 12 hours following removal of aortic cross clamp during weaning from cardiopulmonary bypass</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>tumour necrosis factor (TNF) alpha levels in blood (blood analysis)</outcome>
      <timepoint>0, 1, 2, 3, 6, 12 hours following removal of aortic cross clamp during weaning from cardiopulmonary bypass</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>volume of intravenous fluid infused</outcome>
      <timepoint>12 hours from the commencement of surgery up to 12 hours following surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of vasopressor support</outcome>
      <timepoint>Time until free from intravenous vasoactive support and remains free for remainder of index ICU admission</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patient undergoing high risk cardiac surgery defined as:
(i)	Bentalls procedure
(ii)	Double or triple valve
(iii)	mitral valve replacement
(iv)	coronary artery bypass graft (CABG) + valve replacement
(v)	CABG with ejection fraction&lt;50%
(vi)	Any redo operation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>peripheral vascular disease affecting the upper limbs</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Paul Young</primarysponsorname>
    <primarysponsoraddress>Intensive Care Unit
Wellington Hospital
Private Bag 7902
Wellington South 6021</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Wellington Hospital</fundingname>
      <fundingaddress>Intensive Care Unit
Wellington Hospital
Private Bag 7902
Wellington South 6021</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Victoria University of Wellington</fundingname>
      <fundingaddress>Victoria University of Wellington
PO Box 600
Wellington 6140</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Shawn Sturland</othercollaboratorname>
      <othercollaboratoraddress>Intensive Care Unit
Wellington Hospital
Private Bag 7902
Wellington South 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Sandy Garden</othercollaboratorname>
      <othercollaboratoraddress>c/o Department of Anaesthesia
Wellington Hospital
Private Bag 7902
Wellington South 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Paul Dalley</othercollaboratorname>
      <othercollaboratoraddress>c/o Department of Anaesthesia
Wellington Hospital
Private Bag 7902
Wellington South 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>John Miller</othercollaboratorname>
      <othercollaboratoraddress>School of Biological Sciences
Victoria University of Wellington
PO Box 600
Wellington 6140</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Anne La Flamme</othercollaboratorname>
      <othercollaboratoraddress>School of Biological Sciences
Victoria University of Wellington
PO Box 600
Wellington 6140</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will investigate whether remote ischaemic preconditioning (RIPC) decreases complications after high risk cardiac surgery.  RIPC involves 3 five minute cycles of ischaemia and reperfusion to an arm applied prior to being put on the heart lung machine for heart surgery.  The ischaemia involves inflation of a blood pressure cuff to a level that prevents blood flow to the arm beyond it.  Reperfusion involves releasing the blood pressure cuff.  While on the heart-lung machine, the heart, lungs and abdominal organs receive less blood supply than normal.  There is evidence that RIPC prior to going on the heart-lung machine protects the heart from the decreased blood supply during heart surgery.  We are performing this trial to test whether RIPC decreases the risk of heart, lung, kidney and bleeding complications after cardiac surgery.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Central Region Ethics Committee of Health Research Council of New Zealand</ethicname>
      <ethicaddress>Central Region Ethics Committee of Health Research Council of New Zealand</ethicaddress>
      <ethicapprovaldate>10/02/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>20/11/2009</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Young</name>
      <address>c/o Intensive Care Unit
Wellington Hospital
Private Bag 7902
Wellington South 6021</address>
      <phone>+ 64 4 806 0432</phone>
      <fax>+ 64 4 806 0430</fax>
      <email>paul.young@cchdb.org.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Paul Young</name>
      <address>c/o Intensive Care Unit
Wellington Hospital
Private Bag 7902
Wellington South 6021</address>
      <phone>+ 64 4 806 0432</phone>
      <fax>+ 64 4 806 0430</fax>
      <email>paul.young@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Paul Young</name>
      <address>c/o Intensive Care Unit
Wellington Hospital
Private Bag 7902
Wellington South 6021</address>
      <phone>+ 64 4 806 0432</phone>
      <fax>+ 64 4 806 0430</fax>
      <email>paul.young@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>